Señales en vivo de EPRX.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector...

Stats
Volumen de hoy	15 050.00
Volumen promedio	68 096.00
Capitalización de mercado	132.87M
EPS	$0 ( 2024-04-03 )
Próxima fecha de ganancias	( $-0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.19
ATR14	$0.0180 (0.48%)

Eupraxia Pharmaceuticals Correlación

10 Correlaciones Más Positivas
TCL-A.TO	0.937
CFP.TO	0.902
AQN.TO	0.902
AW-UN.TO	0.901
BLX.TO	0.894
TULB.TO	0.893
WTE.TO	0.893
ESGF.TO	0.89
NPI.TO	0.89
BIP-UN.TO	0.889

10 Correlaciones Más Negativas
SUSA.TO	-0.93
IAF-PI.TO	-0.883
OBE.TO	-0.88
MEG.TO	-0.875
PEY.TO	-0.87
CTZ.V	-0.869
PKI.TO	-0.861
RQK.TO	-0.85
URB.TO	-0.843
VLE.TO	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eupraxia Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-209 911 (0.00 %)
EPS:	$-1.580

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-209 911 (0.00 %)
EPS:	$-1.580

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-193 273 (0.00 %)
EPS:	$-1.210

Financial Reports:

No articles found.

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.